Pharmanet Appoint New Chief Medical Officer
News Feb 21, 2011
In this position, he will be the senior medical representative for the Company and provide guidance to the Company's many physicians who are involved in designing and monitoring Phase I through Phase III clinical trials. He will also retain his current responsibilities heading PharmaNet's team of regulatory and pharmaceutical consultants which provide strategic drug development advice to clients.
"Excellence in pharmaceutical science and medicine is critical to the success of PharmaNet and its clients. We are therefore very pleased that Dr. Jeffrey Freitag, an accomplished internist and nephrologist, will be serving in the role of Chief Medical Officer," said Dr. Tom Newman, President of PharmaNet Development Group.
Dr. Freitag has worked in the pharmaceutical industry for over twenty-five years in a variety of positions including Vice President, Clinical Drug Development at The Liposome Company, Senior Vice President of Medical Affairs at PharmaNet and most recently as Vice President of Research & Development at Bone Care International before rejoining PharmaNet in 2006. Dr. Freitag is board certified in both Internal Medicine and Nephrology and has a strong academic, scientific and clinical background. He has extensive experience in providing medical and scientific direction and leadership to product development teams. He has also provided strategic clinical development consultation to clients in a variety of therapeutic areas including renal, pulmonary, cardiovascular, oncology and infectious disease therapeutic areas.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE